{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T12:23:17Z","timestamp":1789042997594,"version":"build-2803163510"},"reference-count":96,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.leukres.2018.07.025","type":"journal-article","created":{"date-parts":[[2018,8,3]],"date-time":"2018-08-03T16:51:04Z","timestamp":1533315064000},"page":"52-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"special_numbering":"C","title":["IRF4 in multiple myeloma\u2014Biology, disease and therapeutic target"],"prefix":"10.1016","volume":"72","author":[{"given":"Alessandro","family":"Agnarelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Chevassut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9591-7898","authenticated-orcid":false,"given":"Erika J.","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.leukres.2018.07.025_bib0005","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.leukres.2018.07.025_bib0010","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/ajh.24402","article-title":"Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Am. J. Hematol."},{"issue":"12","key":"10.1016\/j.leukres.2018.07.025_bib0015","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.1038\/bcj.2016.118","article-title":"A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival","volume":"6","author":"Botta","year":"2016","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.leukres.2018.07.025_bib0020","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.mayocp.2015.11.007","article-title":"Multiple myeloma: diagnosis and treatment","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Mayo Clin. Proc."},{"issue":"11","key":"10.1016\/j.leukres.2018.07.025_bib0025","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1038\/leu.2017.138","article-title":"Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study","volume":"31","author":"Kumar","year":"2017","journal-title":"Leukemia"},{"issue":"46","key":"10.1016\/j.leukres.2018.07.025_bib0030","doi-asserted-by":"crossref","first-page":"27779","DOI":"10.1074\/jbc.M115.678789","article-title":"Structural studies of IRF4 reveal a flexible autoinhibitory region and a compact linker domain","volume":"290","author":"Remesh","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.leukres.2018.07.025_bib0035","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/ni1357","article-title":"Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination","volume":"7","author":"Klein","year":"2006","journal-title":"Nat. Immunol."},{"issue":"2","key":"10.1016\/j.leukres.2018.07.025_bib0040","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.immuni.2006.07.009","article-title":"Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation","volume":"25","author":"Sciammas","year":"2006","journal-title":"Immunity"},{"issue":"9","key":"10.1016\/j.leukres.2018.07.025_bib0045","doi-asserted-by":"crossref","first-page":"e106788","DOI":"10.1371\/journal.pone.0106788","article-title":"Gene expression profiling identifies IRF4-associated molecular signatures in hematological malignancies","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS One"},{"issue":"7201","key":"10.1016\/j.leukres.2018.07.025_bib0050","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature07064","article-title":"IRF4 addiction in multiple myeloma","volume":"454","author":"Shaffer","year":"2008","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.leukres.2018.07.025_bib0055","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1038\/leu.2015.124","article-title":"Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo","volume":"29","author":"Morelli","year":"2015","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.leukres.2018.07.025_bib0060","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S1097-2765(02)00703-7","article-title":"Crystal structure of PU.1\/IRF-4\/DNA ternary complex","volume":"10","author":"Escalante","year":"2002","journal-title":"Mol. Cell"},{"issue":"4","key":"10.1016\/j.leukres.2018.07.025_bib0065","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1093\/emboj\/18.4.977","article-title":"Assembly requirements of PU.1-Pip (IRF-4) activator complexes: inhibiting function in vivo using fused dimers","volume":"18","author":"Brass","year":"1999","journal-title":"EMBO J."},{"issue":"7421","key":"10.1016\/j.leukres.2018.07.025_bib0070","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nature11531","article-title":"Compensatory dendritic cell development mediated by BATF-IRF interactions","volume":"490","author":"Tussiwand","year":"2012","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.leukres.2018.07.025_bib0075","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.immuni.2013.04.009","article-title":"Transcriptional regulation of germinal center B and plasma cell fates by dynamical control of IRF4","volume":"38","author":"Ochiai","year":"2013","journal-title":"Immunity"},{"issue":"18","key":"10.1016\/j.leukres.2018.07.025_bib0080","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1101\/gad.10.18.2335","article-title":"Pip, a lymphoid-restricted IRF, contains a regulatory domain that is important for autoinhibition and ternary complex formation with the Ets factor PU.1","volume":"10","author":"Brass","year":"1996","journal-title":"Genes Dev."},{"issue":"11","key":"10.1016\/j.leukres.2018.07.025_bib0085","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nsb1002","article-title":"Crystal structure of IRF-3 reveals mechanism of autoinhibition and virus-induced phosphoactivation","volume":"10","author":"Qin","year":"2003","journal-title":"Nat. Struct. Biol."},{"issue":"11","key":"10.1016\/j.leukres.2018.07.025_bib0090","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nsb1001","article-title":"X-ray crystal structure of IRF-3 and its functional implications","volume":"10","author":"Takahasi","year":"2003","journal-title":"Nat. Struct. Biol."},{"issue":"3","key":"10.1016\/j.leukres.2018.07.025_bib0095","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/nri3795","article-title":"The generation of antibody-secreting plasma cells","volume":"15","author":"Nutt","year":"2015","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.leukres.2018.07.025_bib0100","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1600-065X.2012.01124.x","article-title":"Germinal center selection and the development of memory B and plasma cells","volume":"247","author":"Shlomchik","year":"2012","journal-title":"Immunol. Rev."},{"issue":"5","key":"10.1016\/j.leukres.2018.07.025_bib0105","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0092-8674(00)00078-7","article-title":"Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme","volume":"102","author":"Muramatsu","year":"2000","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.leukres.2018.07.025_bib0110","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.4049\/jimmunol.1303216","article-title":"Transcription factor IRF4 regulates germinal center cell formation through a B cell-intrinsic mechanism","volume":"192","author":"Willis","year":"2014","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.leukres.2018.07.025_bib0115","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1074-7613(02)00335-7","article-title":"Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program","volume":"17","author":"Shaffer","year":"2002","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.leukres.2018.07.025_bib0120","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ccr.2007.08.011","article-title":"A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma","volume":"12","author":"Saito","year":"2007","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.leukres.2018.07.025_bib0125","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1600-065X.2012.01112.x","article-title":"Roles of BCL6 in normal and transformed germinal center B cells","volume":"247","author":"Basso","year":"2012","journal-title":"Immunol. Rev."},{"issue":"5","key":"10.1016\/j.leukres.2018.07.025_bib0130","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2009-06-227017","article-title":"Integrated biochemical and computational approach identifies BCL6 direct target genes controlling multiple pathways in normal germinal center B cells","volume":"115","author":"Basso","year":"2010","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.leukres.2018.07.025_bib0135","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1002\/eji.201141553","article-title":"Alternate pathways for Bcl6-mediated regulation of B cell to plasma cell differentiation","volume":"41","author":"Alinikula","year":"2011","journal-title":"Eur. J. Immunol."},{"issue":"7","key":"10.1016\/j.leukres.2018.07.025_bib0140","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1182\/blood-2013-07-518605","article-title":"Cooperative transcriptional repression by BCL6 and BACH2 in germinal center B-cell differentiation","volume":"123","author":"Huang","year":"2014","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.leukres.2018.07.025_bib0145","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/ni.2428","article-title":"c-MYC is required for germinal center selection and cyclic re-entry","volume":"13","author":"Dominguez-Sola","year":"2012","journal-title":"Nat. Immunol."},{"issue":"11","key":"10.1016\/j.leukres.2018.07.025_bib0150","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1038\/ni.2418","article-title":"MYC is essential for the formation and maintenance of germinal centers","volume":"13","author":"Calado","year":"2012","journal-title":"Nat. Immunol."},{"issue":"9","key":"10.1016\/j.leukres.2018.07.025_bib0155","doi-asserted-by":"crossref","first-page":"5427","DOI":"10.4049\/jimmunol.172.9.5427","article-title":"Modular nature of Blimp-1 in the regulation of gene expression during B cell maturation","volume":"172","author":"Sciammas","year":"2004","journal-title":"J. Immunol."},{"issue":"5312","key":"10.1016\/j.leukres.2018.07.025_bib0160","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1126\/science.276.5312.596","article-title":"Repression of c-myc transcription by Blimp-1, an inducer of terminal B cell differentiation","volume":"276","author":"Lin","year":"1997","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.leukres.2018.07.025_bib0165","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.immuni.2009.01.012","article-title":"Stepwise activation of enhancer and promoter regions of the B cell commitment gene Pax5 in early lymphopoiesis","volume":"30","author":"Decker","year":"2009","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.leukres.2018.07.025_bib0170","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.immuni.2007.05.019","article-title":"Transcription factor Pax5 activates the chromatin of key genes involved in B cell signaling, adhesion, migration, and immune function","volume":"27","author":"Schebesta","year":"2007","journal-title":"Immunity"},{"issue":"9","key":"10.1016\/j.leukres.2018.07.025_bib0175","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1084\/jem.20030802","article-title":"The balance between Pax5 and Id2 activities is the key to AID gene expression","volume":"198","author":"Gonda","year":"2003","journal-title":"J. Exp. Med."},{"issue":"13","key":"10.1016\/j.leukres.2018.07.025_bib0180","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1128\/MCB.22.13.4771-4780.2002","article-title":"Blimp-1-dependent repression of Pax-5 is required for differentiation of B cells to immunoglobulin M-secreting plasma cells","volume":"22","author":"Lin","year":"2002","journal-title":"Mol. Cell. Biol."},{"issue":"50","key":"10.1016\/j.leukres.2018.07.025_bib0185","doi-asserted-by":"crossref","first-page":"49047","DOI":"10.1074\/jbc.M205011200","article-title":"Activation of an unfolded protein response during differentiation of antibody-secreting B cells","volume":"277","author":"Gass","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.leukres.2018.07.025_bib0190","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/ni.3348","article-title":"Blimp-1 controls plasma cell function through the regulation of immunoglobulin secretion and the unfolded protein response","volume":"17","author":"Tellier","year":"2016","journal-title":"Nat. Immunol."},{"issue":"8","key":"10.1016\/j.leukres.2018.07.025_bib0195","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1182\/bloodadvances.2017010413","article-title":"Zinc finger-IRF composite elements bound by Ikaros\/IRF4 complexes function as gene repression in plasma cell","volume":"2","author":"Ochiai","year":"2018","journal-title":"Blood Adv."},{"issue":"49","key":"10.1016\/j.leukres.2018.07.025_bib0200","doi-asserted-by":"crossref","first-page":"85392","DOI":"10.18632\/oncotarget.19907","article-title":"Bone marrow IRF4 level in multiple myeloma: an indicator of peripheral blood Th17 and disease","volume":"8","author":"Bai","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.leukres.2018.07.025_bib0205","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/ng1097-226","article-title":"Deregulation of MUM1\/IRF4 by chromosomal translocation in multiple myeloma","volume":"17","author":"Iida","year":"1997","journal-title":"Nat. Genet."},{"issue":"11","key":"10.1016\/j.leukres.2018.07.025_bib0210","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1038\/sj.leu.2401563","article-title":"Detection of MUM1\/IRF4-IgH fusion in multiple myeloma","volume":"13","author":"Yoshida","year":"1999","journal-title":"Leukemia"},{"issue":"7339","key":"10.1016\/j.leukres.2018.07.025_bib0215","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nature09837","article-title":"Initial genome sequencing and analysis of multiple myeloma","volume":"471","author":"Chapman","year":"2011","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.leukres.2018.07.025_bib0220","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","article-title":"Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy","volume":"25","author":"Lohr","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2018.07.025_bib0225","article-title":"Epigenetics in multiple myeloma: from mechanisms to therapy","author":"Alzrigat","year":"2017","journal-title":"Semin. Cancer Biol."},{"issue":"17","key":"10.1016\/j.leukres.2018.07.025_bib0230","doi-asserted-by":"crossref","first-page":"6934","DOI":"10.1158\/0008-5472.CAN-10-0282","article-title":"DNA methylation analysis determines the high frequency of genic hypomethylation and low frequency of hypermethylation events in plasma cell tumors","volume":"70","author":"Salhia","year":"2010","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.leukres.2018.07.025_bib0235","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1182\/blood-2010-04-279539","article-title":"Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma","volume":"117","author":"Walker","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2018.07.025_bib0240","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.4049\/jimmunol.1202493","article-title":"Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis","volume":"190","author":"Heuck","year":"2013","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.leukres.2018.07.025_bib0245","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/carcin\/bgp149","article-title":"Differential repetitive DNA methylation in multiple myeloma molecular subgroups","volume":"30","author":"Bollati","year":"2009","journal-title":"Carcinogenesis"},{"issue":"3","key":"10.1016\/j.leukres.2018.07.025_bib0250","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/bjh.13506","article-title":"Global hypomethylation in myeloma is associated with poor prognosis","volume":"172","author":"Sive","year":"2016","journal-title":"Br. J. Haematol."},{"issue":"12","key":"10.1016\/j.leukres.2018.07.025_bib0255","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1182\/blood-2003-12-4114","article-title":"Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines","volume":"104","author":"Houde","year":"2004","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2018.07.025_bib0260","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.yexmp.2008.02.003","article-title":"Aberrant gene promoter methylation in plasma cell dyscrasias","volume":"84","author":"Martin","year":"2008","journal-title":"Exp. Mol. Pathol."},{"issue":"4","key":"10.1016\/j.leukres.2018.07.025_bib0265","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1101\/gr.180240.114","article-title":"Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers","volume":"25","author":"Agirre","year":"2015","journal-title":"Genome Res."},{"issue":"5","key":"10.1016\/j.leukres.2018.07.025_bib0270","doi-asserted-by":"crossref","first-page":"e97953","DOI":"10.1371\/journal.pone.0097953","article-title":"KLF2--a negative regulator of pre-B cell clonal expansion and B cell activation","volume":"9","author":"Winkelmann","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.leukres.2018.07.025_bib0275","doi-asserted-by":"crossref","first-page":"10258","DOI":"10.1038\/ncomms10258","article-title":"The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival","volume":"7","author":"Ohguchi","year":"2016","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.leukres.2018.07.025_bib0280","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.cell.2006.03.027","article-title":"JHDM2A, a JmjC-containing H3K9 demethylase, facilitates transcription activation by androgen receptor","volume":"125","author":"Yamane","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.leukres.2018.07.025_bib0285","doi-asserted-by":"crossref","first-page":"13656","DOI":"10.1038\/ncomms13656","article-title":"Multiple myeloma risk variant at 7p15.3 creates an IRF4-binding site and interferes with CDCA7L expression","volume":"7","author":"Li","year":"2016","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.leukres.2018.07.025_bib0290","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2141.2011.08689.x","article-title":"Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response","volume":"154","author":"Lopez-Girona","year":"2011","journal-title":"Br. J. Haematol."},{"issue":"23","key":"10.1016\/j.leukres.2018.07.025_bib0295","doi-asserted-by":"crossref","first-page":"8684","DOI":"10.1128\/MCB.20.23.8684-8695.2000","article-title":"Repression of c-myc is necessary but not sufficient for terminal differentiation of B lymphocytes in vitro","volume":"20","author":"Lin","year":"2000","journal-title":"Mol. Cell. Biol."},{"issue":"7","key":"10.1016\/j.leukres.2018.07.025_bib0300","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/cdd.2015.167","article-title":"Aiolos collaborates with Blimp-1 to regulate the survival of multiple myeloma cells","volume":"23","author":"Hung","year":"2016","journal-title":"Cell Death Differ."},{"issue":"6","key":"10.1016\/j.leukres.2018.07.025_bib0305","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.4049\/jimmunol.170.6.3125","article-title":"Identification of a functionally impaired positive regulatory domain I binding factor 1 transcription repressor in myeloma cell lines","volume":"170","author":"Gyory","year":"2003","journal-title":"J. Immunol."},{"issue":"11","key":"10.1016\/j.leukres.2018.07.025_bib0310","first-page":"1579","article-title":"The expression of PRDI-BF1 beta isoform in multiple myeloma plasma cells","volume":"91","author":"Ocana","year":"2006","journal-title":"Haematologica"},{"issue":"26","key":"10.1016\/j.leukres.2018.07.025_bib0315","doi-asserted-by":"crossref","first-page":"15933","DOI":"10.1074\/jbc.273.26.15933","article-title":"The PR domain of the Rb-binding zinc finger protein RIZ1 is a protein binding interface and is related to the SET domain functioning in chromatin-mediated gene expression","volume":"273","author":"Huang","year":"1998","journal-title":"J. Biol. Chem."},{"issue":"18","key":"10.1016\/j.leukres.2018.07.025_bib0320","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1182\/blood-2010-02-270082","article-title":"A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells","volume":"115","author":"Hideshima","year":"2010","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.leukres.2018.07.025_bib0325","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1111\/cas.13283","article-title":"Overexpression of B-cell lymphoma 6 alters gene expression profile in a myeloma cell line and is associated with decreased DNA damage response","volume":"108","author":"Tahara","year":"2017","journal-title":"Cancer Sci."},{"key":"10.1016\/j.leukres.2018.07.025_bib0330","doi-asserted-by":"crossref","first-page":"4812637","DOI":"10.1155\/2017\/4812637","article-title":"The evolution of prognostic factors in multiple myeloma","volume":"2017","author":"Hanbali","year":"2017","journal-title":"Adv. Hematol."},{"issue":"1","key":"10.1016\/j.leukres.2018.07.025_bib0335","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13045-016-0282-1","article-title":"Novel agents in the treatment of multiple myeloma: a review about the future","volume":"9","author":"Naymagon","year":"2016","journal-title":"J. Hematol. Oncol."},{"issue":"5299","key":"10.1016\/j.leukres.2018.07.025_bib0340","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1126\/science.275.5299.540","article-title":"Requirement for the transcription factor LSIRF\/IRF4 for mature B and T lymphocyte function","volume":"275","author":"Mittrucker","year":"1997","journal-title":"Science"},{"issue":"6168","key":"10.1016\/j.leukres.2018.07.025_bib0345","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"issue":"6168","key":"10.1016\/j.leukres.2018.07.025_bib0350","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kronke","year":"2014","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.leukres.2018.07.025_bib0355","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1182\/blood-2014-02-557819","article-title":"Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma","volume":"124","author":"Zhu","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2018.07.025_bib0360","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.yexcr.2018.01.005","article-title":"Crucial role of HO-1\/IRF4-dependent apoptosis induced by panobinostat and lenalidomide in multiple myeloma","volume":"363","author":"Tang","year":"2018","journal-title":"Exp. Cell Res."},{"issue":"48","key":"10.1016\/j.leukres.2018.07.025_bib0365","doi-asserted-by":"crossref","first-page":"79064","DOI":"10.18632\/oncotarget.12594","article-title":"Synergistic targeting of Sp1, a critical transcription factor for myeloma cell growth and survival, by panobinostat and proteasome inhibitors","volume":"7","author":"Bat-Erdene","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.leukres.2018.07.025_bib0370","article-title":"Bromodomain inhibition of the transcriptional coactivators CBP\/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma","volume":"5","author":"Conery","year":"2016","journal-title":"Elife"},{"issue":"7674","key":"10.1016\/j.leukres.2018.07.025_bib0375","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nature24028","article-title":"Discovery of a selective catalytic p300\/CBP inhibitor that targets lineage-specific tumours","volume":"550","author":"Lasko","year":"2017","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.leukres.2018.07.025_bib0380","doi-asserted-by":"crossref","first-page":"10213","DOI":"10.18632\/oncotarget.14378","article-title":"EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions","volume":"8","author":"Alzrigat","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.leukres.2018.07.025_bib0385","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s13045-016-0362-2","article-title":"Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay","volume":"9","author":"Abruzzese","year":"2016","journal-title":"J. Hematol. Oncol."},{"issue":"27","key":"10.1016\/j.leukres.2018.07.025_bib0390","doi-asserted-by":"crossref","first-page":"23609","DOI":"10.18632\/oncotarget.4603","article-title":"The IMiDs targets IKZF-1\/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma","volume":"6","author":"Fionda","year":"2015","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.leukres.2018.07.025_bib0395","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1182\/blood-2011-08-371567","article-title":"Addiction to c-MYC in multiple myeloma","volume":"120","author":"Holien","year":"2012","journal-title":"Blood"},{"issue":"40","key":"10.1016\/j.leukres.2018.07.025_bib0400","doi-asserted-by":"crossref","first-page":"16669","DOI":"10.1073\/pnas.1108190108","article-title":"Targeting MYC dependence in cancer by inhibiting BET bromodomains","volume":"108","author":"Mertz","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.leukres.2018.07.025_bib0405","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.leukres.2018.07.025_bib0410","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.cyto.2014.11.013","article-title":"Bromodomain inhibition by JQ1 suppresses lipopolysaccharide-stimulated interleukin-6 secretion in multiple myeloma cells","volume":"71","author":"Ghurye","year":"2015","journal-title":"Cytokine"},{"issue":"5","key":"10.1016\/j.leukres.2018.07.025_bib0415","first-page":"e620","article-title":"Bromodomain inhibitor review: bromodomain and extra-terminal family protein inhibitors as a potential new therapy in central nervous system tumors","volume":"8","author":"Wadhwa","year":"2016","journal-title":"Cureus"},{"issue":"5","key":"10.1016\/j.leukres.2018.07.025_bib0420","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2013-01-478420","article-title":"Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762","volume":"123","author":"Chaidos","year":"2014","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.leukres.2018.07.025_bib0425","doi-asserted-by":"crossref","first-page":"18921","DOI":"10.18632\/oncotarget.4214","article-title":"Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma","volume":"6","author":"Siegel","year":"2015","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.leukres.2018.07.025_bib0430","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/15592294.2016.1265710","article-title":"Bromodomain inhibitors and cancer therapy: From structures to applications","volume":"12","author":"Perez-Salvia","year":"2017","journal-title":"Epigenetics"},{"issue":"11","key":"10.1016\/j.leukres.2018.07.025_bib0435","doi-asserted-by":"crossref","first-page":"5328","DOI":"10.1158\/0008-5472.CAN-06-4265","article-title":"Down-regulation of PU.1 by methylation of distal regulatory elements and the promoter is required for myeloma cell growth","volume":"67","author":"Tatetsu","year":"2007","journal-title":"Cancer Res."},{"issue":"31","key":"10.1016\/j.leukres.2018.07.025_bib0440","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.1038\/onc.2017.79","article-title":"PU.1 acts as tumor suppressor for myeloma cells through direct transcriptional repression of IRF4","volume":"36","author":"Ueno","year":"2017","journal-title":"Oncogene"},{"issue":"24","key":"10.1016\/j.leukres.2018.07.025_bib0445","doi-asserted-by":"crossref","first-page":"11914","DOI":"10.1158\/0008-5472.CAN-07-1868","article-title":"Induction of apoptosis in plasma cells by B lymphocyte-induced maturation protein-1 knockdown","volume":"67","author":"Lin","year":"2007","journal-title":"Cancer Res."},{"issue":"24","key":"10.1016\/j.leukres.2018.07.025_bib0450","doi-asserted-by":"crossref","first-page":"5772","DOI":"10.1182\/blood-2011-07-366633","article-title":"Blockade of XBP1 splicing by inhibition of IRE1alpha is a promising therapeutic option in multiple myeloma","volume":"119","author":"Mimura","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.07.025_bib0455","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/B978-0-12-407704-1.00005-1","article-title":"Endoplasmic reticulum and the unfolded protein response: dynamics and metabolic integration","volume":"301","author":"Bravo","year":"2013","journal-title":"Int. Rev. Cell Mol. Biol."},{"issue":"3","key":"10.1016\/j.leukres.2018.07.025_bib0460","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ccr.2013.08.009","article-title":"Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma","volume":"24","author":"Leung-Hagesteijn","year":"2013","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.leukres.2018.07.025_bib0465","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.4049\/jimmunol.1101230","article-title":"Characterization of a transitional preplasmablast population in the process of human B cell to plasma cell differentiation","volume":"187","author":"Jourdan","year":"2011","journal-title":"J. Immunol."},{"issue":"6844","key":"10.1016\/j.leukres.2018.07.025_bib0470","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/35085509","article-title":"Plasma cell differentiation requires the transcription factor XBP-1","volume":"412","author":"Reimold","year":"2001","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.leukres.2018.07.025_bib0475","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1002\/jcb.25605","article-title":"Transcription factor drug targets","volume":"117","author":"Papavassiliou","year":"2016","journal-title":"J. Cell. Biochem."},{"issue":"1","key":"10.1016\/j.leukres.2018.07.025_bib0480","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.trecan.2015.07.001","article-title":"Targeting transcription factors in cancer","volume":"1","author":"Bhagwat","year":"2015","journal-title":"Trends Cancer"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212618301772?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212618301772?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T05:17:56Z","timestamp":1717219076000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212618301772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":96,"alternative-id":["S0145212618301772"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2018.07.025","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IRF4 in multiple myeloma\u2014Biology, disease and therapeutic target","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2018.07.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}